The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat

E. Tsuchida, Ross Bullock

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Acute subdural hematoma (SDH) complicates about 20% of severely head- injured patients, and death and severe disability frequently result, yet over half of these patients may have been conscious, at some time after injury, implying secondary mechanisms of brain damage. Drugs that block the 'excitotoxic' effects of glutamate at the N-methyl-D-aspartate (NMDA) receptor have generally been effective in reducing ischemic brain damage associated with SDH in animal models, yet these agents all appear to be associated with major behavioral side effects, in conscious patients, at neuroprotective doses. We therefore evaluated the effects of treatment with a novel antagonist for the glycine binding site of the NMDA receptor (ACEA1021) upon ischemic brain damage, in the rat SDH model. ACEA1021 may be free of psychomotor effects, and may thus permit high dose therapy in conscious trauma and stroke patients. SDH was produced by the slow injection of 0.4 mL autologous blood into the subdural space overlying the parietal cortex. Brain damage was assessed histologically at 8 coronal planes, in animals sacrificed 4 h after induction of hematoma. Both pre and posttreatment with ACEA1021 significantly reduced hemispheric ischemic damage produced by SDH. The magnitude of neuroprotection with this compound (26 to 39% reduction in infarct size) is similar to other NMDA antagonists, and the robust posttreatment effect implies that human studies with this compound should be performed in head injured patients, subject to completion of toxicology testing.

Original languageEnglish
Pages (from-to)279-288
Number of pages10
JournalJournal of Neurotrauma
Volume12
Issue number3
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Hematoma, Subdural, Acute
N-Methylaspartate
Subdural Hematoma
Glycine
Brain
N-Methyl-D-Aspartate Receptors
Subdural Space
Head
Parietal Lobe
Wounds and Injuries
Hematoma
Toxicology
Glutamic Acid
Animal Models
Stroke
Binding Sites
Injections
Therapeutics
Pharmaceutical Preparations

Keywords

  • ACEA 1021
  • acute subdural hematoma
  • glycine binding site
  • ischemic brain damage
  • NMDA antagonist
  • rat

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat. / Tsuchida, E.; Bullock, Ross.

In: Journal of Neurotrauma, Vol. 12, No. 3, 01.01.1995, p. 279-288.

Research output: Contribution to journalArticle

@article{85bdb30fea1f4cffa2555829a8eb324e,
title = "The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat",
abstract = "Acute subdural hematoma (SDH) complicates about 20{\%} of severely head- injured patients, and death and severe disability frequently result, yet over half of these patients may have been conscious, at some time after injury, implying secondary mechanisms of brain damage. Drugs that block the 'excitotoxic' effects of glutamate at the N-methyl-D-aspartate (NMDA) receptor have generally been effective in reducing ischemic brain damage associated with SDH in animal models, yet these agents all appear to be associated with major behavioral side effects, in conscious patients, at neuroprotective doses. We therefore evaluated the effects of treatment with a novel antagonist for the glycine binding site of the NMDA receptor (ACEA1021) upon ischemic brain damage, in the rat SDH model. ACEA1021 may be free of psychomotor effects, and may thus permit high dose therapy in conscious trauma and stroke patients. SDH was produced by the slow injection of 0.4 mL autologous blood into the subdural space overlying the parietal cortex. Brain damage was assessed histologically at 8 coronal planes, in animals sacrificed 4 h after induction of hematoma. Both pre and posttreatment with ACEA1021 significantly reduced hemispheric ischemic damage produced by SDH. The magnitude of neuroprotection with this compound (26 to 39{\%} reduction in infarct size) is similar to other NMDA antagonists, and the robust posttreatment effect implies that human studies with this compound should be performed in head injured patients, subject to completion of toxicology testing.",
keywords = "ACEA 1021, acute subdural hematoma, glycine binding site, ischemic brain damage, NMDA antagonist, rat",
author = "E. Tsuchida and Ross Bullock",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "12",
pages = "279--288",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of the glycine site-specific N-methyl-D-aspartate antagonist ACEA1021 on ischemic brain damage caused by acute subdural hematoma in the rat

AU - Tsuchida, E.

AU - Bullock, Ross

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Acute subdural hematoma (SDH) complicates about 20% of severely head- injured patients, and death and severe disability frequently result, yet over half of these patients may have been conscious, at some time after injury, implying secondary mechanisms of brain damage. Drugs that block the 'excitotoxic' effects of glutamate at the N-methyl-D-aspartate (NMDA) receptor have generally been effective in reducing ischemic brain damage associated with SDH in animal models, yet these agents all appear to be associated with major behavioral side effects, in conscious patients, at neuroprotective doses. We therefore evaluated the effects of treatment with a novel antagonist for the glycine binding site of the NMDA receptor (ACEA1021) upon ischemic brain damage, in the rat SDH model. ACEA1021 may be free of psychomotor effects, and may thus permit high dose therapy in conscious trauma and stroke patients. SDH was produced by the slow injection of 0.4 mL autologous blood into the subdural space overlying the parietal cortex. Brain damage was assessed histologically at 8 coronal planes, in animals sacrificed 4 h after induction of hematoma. Both pre and posttreatment with ACEA1021 significantly reduced hemispheric ischemic damage produced by SDH. The magnitude of neuroprotection with this compound (26 to 39% reduction in infarct size) is similar to other NMDA antagonists, and the robust posttreatment effect implies that human studies with this compound should be performed in head injured patients, subject to completion of toxicology testing.

AB - Acute subdural hematoma (SDH) complicates about 20% of severely head- injured patients, and death and severe disability frequently result, yet over half of these patients may have been conscious, at some time after injury, implying secondary mechanisms of brain damage. Drugs that block the 'excitotoxic' effects of glutamate at the N-methyl-D-aspartate (NMDA) receptor have generally been effective in reducing ischemic brain damage associated with SDH in animal models, yet these agents all appear to be associated with major behavioral side effects, in conscious patients, at neuroprotective doses. We therefore evaluated the effects of treatment with a novel antagonist for the glycine binding site of the NMDA receptor (ACEA1021) upon ischemic brain damage, in the rat SDH model. ACEA1021 may be free of psychomotor effects, and may thus permit high dose therapy in conscious trauma and stroke patients. SDH was produced by the slow injection of 0.4 mL autologous blood into the subdural space overlying the parietal cortex. Brain damage was assessed histologically at 8 coronal planes, in animals sacrificed 4 h after induction of hematoma. Both pre and posttreatment with ACEA1021 significantly reduced hemispheric ischemic damage produced by SDH. The magnitude of neuroprotection with this compound (26 to 39% reduction in infarct size) is similar to other NMDA antagonists, and the robust posttreatment effect implies that human studies with this compound should be performed in head injured patients, subject to completion of toxicology testing.

KW - ACEA 1021

KW - acute subdural hematoma

KW - glycine binding site

KW - ischemic brain damage

KW - NMDA antagonist

KW - rat

UR - http://www.scopus.com/inward/record.url?scp=0029132006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029132006&partnerID=8YFLogxK

M3 - Article

C2 - 7473802

AN - SCOPUS:0029132006

VL - 12

SP - 279

EP - 288

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 3

ER -